Suppr超能文献

隐源性机化性肺炎——克拉霉素与皮质类固醇治疗结果——观察性研究

Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study.

作者信息

Radzikowska Elżbieta, Wiatr Elżbieta, Langfort Renata, Bestry Iwona, Skoczylas Agnieszka, Szczepulska-Wójcik Ewa, Gawryluk Dariusz, Rudziński Piotr, Chorostowska-Wynimko Joanna, Roszkowski-Śliż Kazimierz

机构信息

III Department of Lung Disease National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.

Pathology Department National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland.

出版信息

PLoS One. 2017 Sep 25;12(9):e0184739. doi: 10.1371/journal.pone.0184739. eCollection 2017.

Abstract

BACKGROUND

Cryptogenic organizing pneumonia (COP) is a clinicopathological syndrome of unknown origin. Corticosteroids are the standard treatment, but clarithromycin (CAM) is also effective. The aim of this observational retrospective study was to compare the results of CAM versus prednisone (PRE) treatment in patients with biopsy-proven OP without respiratory insufficiency.

MATERIAL AND METHODS

In a 15-year period, 40 patients were treated with CAM (500 mg twice daily orally for 3 months) and 22 with PRE (mean initial dose of 0.67 ± 0.24 mg/kg/d for a mean of 8.59 ± 3.05 months).

RESULTS

The clinical presentation, laboratory, and radiological findings did not differ markedly between patients treated with CAM and PRE, with the exception of a higher frequency of sweats (55% vs. 23%; p < 0.015), ground glass opacities (95% vs. 50%; p <0.0001) and nodular lesions (45% vs. 18%; p = 0.036) in the CAM group. A complete response was achieved in 35(88%) patients treated with CAM and in all treated with PRE. Patients treated with PRE relapsed more frequently than those treated with CAM (54.5% vs. 10%; p < 0.0001). Corticosteroid-related adverse events were noticed in 8(6.5%) patients (with one death), but CAM caused only one (2.5%) allergic reaction. A FVC >80% identified patients who might be successfully treated with CAM with a sensitivity of 60% and a specificity of 88.57% (AUC 0.869; 95% CI 0.684-1; p = 0.008); the figures for the FEV1 were >70%, a sensitivity of 60%, and a specificity of 91.43% (AUC 0.809; 95%CI 0.609-1; p = 0.027).

CONCLUSIONS

CAM can be used to treat COP patients in whom the pulmonary function parameters are within normal limits. Such therapy is shorter, better tolerated, and associated with fewer adverse events and relapses than is PRE. However, the therapy is ineffective in some patients.

摘要

背景

隐源性机化性肺炎(COP)是一种病因不明的临床病理综合征。皮质类固醇是标准治疗方法,但克拉霉素(CAM)也有效。这项观察性回顾性研究的目的是比较CAM与泼尼松(PRE)治疗活检证实为OP且无呼吸功能不全患者的结果。

材料与方法

在15年期间,40例患者接受CAM治疗(口服500mg,每日两次,共3个月),22例接受PRE治疗(平均初始剂量为0.67±0.24mg/kg/d,平均治疗8.59±3.05个月)。

结果

接受CAM和PRE治疗的患者临床表现、实验室检查和影像学表现无明显差异,但CAM组出汗频率更高(55%对23%;p<0.015)、磨玻璃影更多见(95%对50%;p<0.0001)以及结节性病变更多(45%对18%;p=0.036)。接受CAM治疗的35例(88%)患者和所有接受PRE治疗的患者均实现了完全缓解。接受PRE治疗的患者比接受CAM治疗的患者复发更频繁(54.5%对10%;p<0.0001)。8例(6.5%)患者出现了与皮质类固醇相关的不良事件(1例死亡),但CAM仅引起1例(2.5%)过敏反应。用力肺活量(FVC)>80%可识别出可能用CAM成功治疗的患者,敏感性为60%,特异性为88.57%(曲线下面积[AUC]0.869;95%置信区间[CI]0.684 - 1;p = 0.008);第1秒用力呼气容积(FEV1)的相应数据为>70%,敏感性为60%,特异性为91.43%(AUC 0.809;95%CI 0.609 - 1;p = 0.027)。

结论

CAM可用于治疗肺功能参数在正常范围内的COP患者。与PRE相比,这种治疗疗程更短、耐受性更好,不良事件和复发更少。然而,该治疗对部分患者无效。

相似文献

1
Cryptogenic organizing pneumonia-Results of treatment with clarithromycin versus corticosteroids-Observational study.
PLoS One. 2017 Sep 25;12(9):e0184739. doi: 10.1371/journal.pone.0184739. eCollection 2017.
2
[Organizing pneumonia--clarithromycin treatment].
Pneumonol Alergol Pol. 2008;76(5):334-9.
4
A long-term retrospective study of patients with biopsy-proven cryptogenic organizing pneumonia.
Chron Respir Dis. 2019 Jan-Dec;16:1479973119853829. doi: 10.1177/1479973119853829.
5
Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia.
Ann Am Thorac Soc. 2014 Jan;11(1):87-91. doi: 10.1513/AnnalsATS.201308-261CR.
8
[Organizing pneumonia--analysis of 18 own cases].
Pneumonol Alergol Pol. 2004;72(3-4):99-104.
9
Successful salvage treatment of steroid-refractory bronchiolar COP with low-dose macrolides.
Pathol Int. 2012 Feb;62(2):144-8. doi: 10.1111/j.1440-1827.2011.02766.x. Epub 2011 Nov 30.
10
Comparison between cryptogenic organizing pneumonia and connective tissue disease-related organizing pneumonia.
Rheumatology (Oxford). 2011 May;50(5):932-8. doi: 10.1093/rheumatology/keq410. Epub 2010 Dec 17.

引用本文的文献

1
Korean Guidelines for Diagnosis and Management of Interstitial Lung Disease: Cryptogenic Organizing Pneumonia.
Tuberc Respir Dis (Seoul). 2025 Jul;88(3):477-487. doi: 10.4046/trd.2024.0167. Epub 2025 Mar 13.
2
Application of Innovative 3D Pathological Tactic for Diagnosis of Organizing Pneumonia.
In Vivo. 2024 Jul-Aug;38(4):1993-2000. doi: 10.21873/invivo.13656.
3
How I diagnose and treat organizing pneumonia in hematopoietic cell transplant recipients.
Blood. 2024 Sep 5;144(10):1048-1060. doi: 10.1182/blood.2023023249.
4
Corticosteroid treatment for persistent pulmonary infiltrates following COVID-19 infection: Clearing the fog?
Ann Thorac Med. 2024 Jan-Mar;19(1):74-80. doi: 10.4103/atm.atm_121_23. Epub 2024 Jan 25.
5
Case report: Coexistence of triple-seronegative myasthenia gravis and pathology-proven cryptogenic organizing pneumonia.
Front Neurol. 2023 Nov 16;14:1295374. doi: 10.3389/fneur.2023.1295374. eCollection 2023.
6
Delayed organising pneumonia in an immunocompromised host after a mild COVID-19 infection.
BMJ Case Rep. 2023 May 16;16(5):e254737. doi: 10.1136/bcr-2023-254737.
7
Update on cryptogenic organizing pneumonia.
Front Med (Lausanne). 2023 Apr 20;10:1146782. doi: 10.3389/fmed.2023.1146782. eCollection 2023.
8
Clarithromycin in Post COVID-19 Organizing pneumonia.
Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(3):e2022025. doi: 10.36141/svdld.v39i3.13003. Epub 2022 Sep 23.
9
The Hidden Pandemic of COVID-19-Induced Organizing Pneumonia.
Pharmaceuticals (Basel). 2022 Dec 16;15(12):1574. doi: 10.3390/ph15121574.
10
Rituximab for steroid-resistant organising pneumonia in a woman with rheumatoid arthritis.
BMJ Case Rep. 2022 Nov 1;15(11):e249912. doi: 10.1136/bcr-2022-249912.

本文引用的文献

3
A randomised controlled trial of azithromycin therapy in bronchiolitis obliterans syndrome (BOS) post lung transplantation.
Thorax. 2015 May;70(5):442-50. doi: 10.1136/thoraxjnl-2014-205998. Epub 2015 Feb 24.
4
Macrolide therapy in cryptogenic organizing pneumonia: A case report and literature review.
Exp Ther Med. 2015 Mar;9(3):829-834. doi: 10.3892/etm.2015.2183. Epub 2015 Jan 15.
5
Gastroesophageal reflux disease is a risk factor for severity of organizing pneumonia.
Respiration. 2015;89(2):119-26. doi: 10.1159/000369470. Epub 2015 Jan 28.
7
Macrolide use leads to clinical and radiological improvement in patients with cryptogenic organizing pneumonia.
Ann Am Thorac Soc. 2014 Jan;11(1):87-91. doi: 10.1513/AnnalsATS.201308-261CR.
8
Macrolides inhibit cytokine production by alveolar macrophages in bronchiolitis obliterans organizing pneumonia.
Immunobiology. 2013 Jun;218(6):930-7. doi: 10.1016/j.imbio.2012.10.014. Epub 2012 Nov 2.
9
Macrolide antibiotics for cystic fibrosis.
Cochrane Database Syst Rev. 2012 Nov 14;11(11):CD002203. doi: 10.1002/14651858.CD002203.pub4.
10
Comparison between cryptogenic organizing pneumonia and connective tissue disease-related organizing pneumonia.
Rheumatology (Oxford). 2011 May;50(5):932-8. doi: 10.1093/rheumatology/keq410. Epub 2010 Dec 17.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验